Highlights

2009

Biocon completes Phase 2 clinical trials in Psoriasis.

Biocon initiates IN-105 Phase 3 study in Type 2 diabetes.

Biocon completed Phase 3 studies using Insulin Glargine and have got regulatory approval for Marketing.

2008

Biocon presents data on oral insulin at the European Association for Study of Diabetes, Rome.

Biocon completed Phase 2 studies using IN-105 (oral insulin) in T2DM subjects.

Biocon initiates Phase 2 studies using T1h in Psoriasis patients.

Biocon completes Phase 1 clinical trial using IN-105 in NHV in Europe.

Biocon initiates collaboration with Iatrica Inc. on development on novel NucleoMabs for Oncology.

2007

Biocon initiates Phase 1 Clinical Trials in Europe after getting approvals from the MPA (Sweden).

Biocon initiates clinical trial of T1h in Rheumatoid Arthritis.

Additional clinical trials for use of BIOMAb EGFR™ in the treatment of glioma and non-small cell lung carcinoma initiated.

Biocon unveils five renal therapy drugs.

Biocon gets regulatory approval for GCSF.

Biocon gets regulatory approval for Streptokinase.

Biocon signs pact with Deakin University to jointly develop a mammalian cell bio-processing facility.

2006

Biocon files PCT for novel process of manufacturing of Oral Insulin.

Biocon completes phase-IV trials of INSUGEN®.

Biocon launches BIOMAb-EGFR™, a therapeutic monoclonal antibody-based drug for treating solid tumors of epithelial origin.

2005

Biocon acquires the intellectual property of Nobex Corporation. With it, Biocon's total IP estate increases by nearly 300 patents and patent applications focused on oral peptide therapeutics in the metabolic and cardiovascular segment.

Biocon and Karolinska Institute sign a MoU to collaborate in research and research education initiatives.

2004

Biocon and Vaccinex partner to discover and develop therapeutic antibodies.

Biocon launches INSUGEN®, the world's first recombinant human (r-DNA) insulin using a unique Pichia expression system.

2003

Biocon files its 100th patent application.

2002

Biocon ranks 3rd among Indian companies for filing PCT applications.

Biocon files PCT application for patent on 'Methods of producing esters of Mycophenolate'.

US patent office grants 3 patents on the process for the manufacture of Simvastatin.

FDA approves a solid state process for the manufacture of Lovastatin.

2001

US patent office grants a patent on PlaFractor™, Biocon's revolutionary bioreactor.